Cambridge, UK-based GW Pharmaceuticals is a biopharmaceutical company that is engaged in developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It is the third-largest marijuana company with a market capitalization of $4.28 billion.The company’s lead product is Epidiolex, a cannabidoil-based drug that is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. Epidiolex has received orphan drug and fast-track designation from the U.S. Food and Drug Administration.